CELL BIOLOGY • GENE EXPRESSION AND REGULATION

RNA Processing — Explain RNA processing (capping, splicing, polyadenylation) and alternative splicing (conceptual)

How eukaryotic cells sculpt nascent transcripts into mature, functional messenger RNA through sequential co-transcriptional modifications.

Historical Context & Motivation

For decades after the elucidation of the central dogma, the path from gene to protein appeared deceptively simple: DNA is transcribed into messenger RNA, which is then translated into protein. Yet careful biochemical analyses in the 1970s revealed that eukaryotic genes harbor vast stretches of non-coding sequence—introns—that must be physically excised from the nascent transcript before it can serve as a template for translation. This discovery upended the one-gene-one-mRNA paradigm and revealed an elaborate suite of processing events that transform pre-mRNA into a mature, export-competent messenger.

Understanding RNA processing is essential because it represents a major regulatory checkpoint in eukaryotic gene expression. Defects in capping, splicing, or polyadenylation are implicated in numerous human diseases, from spinal muscular atrophy to certain cancers. Moreover, the phenomenon of alternative splicing dramatically expands the proteomic diversity of an organism far beyond the raw gene count—explaining, for instance, how the human genome's approximately 20,000 genes can encode over 100,000 distinct protein isoforms.

1975
Discovery of the 5ʹ Cap
Furuichi, Shatkin, and colleagues identified the 7-methylguanosine cap structure at the 5ʹ end of eukaryotic mRNAs, revealing the first known co-transcriptional modification.
1977
Split Genes & Introns
Richard Roberts and Phillip Sharp independently demonstrated that adenovirus genes are discontinuous—containing intervening sequences (introns) spliced out of mRNA—earning the 1993 Nobel Prize.
1981
Polyadenylation Signal Defined
Proudfoot and Brownlee characterized the AAUAAA consensus hexamer as the primary signal directing 3ʹ cleavage and polyadenylation in mammalian transcripts.
1982
Spliceosome Discovery
Joan Steitz and colleagues identified small nuclear ribonucleoproteins (snRNPs) as components of a large RNA-protein machine—the spliceosome—that catalyzes intron removal.
2015
Cryo-EM Spliceosome Structure
Near-atomic-resolution cryo-electron microscopy structures of the spliceosome in multiple catalytic states provided mechanistic insight into the two-step transesterification reaction.

The central question that RNA processing answers is this: how does the eukaryotic cell convert a raw transcript—complete with introns, unprotected termini, and no quality control—into a stable, properly addressed message that can be exported from the nucleus and faithfully decoded on the ribosome? The answer lies in three coordinated modifications: 5ʹ capping, splicing, and 3ʹ polyadenylation.

Core Principles of RNA Processing

RNA processing in eukaryotes is governed by several fundamental principles that distinguish it from the comparatively streamlined gene expression of prokaryotes. These modifications are not mere afterthoughts; they are intimately coupled to transcription itself, occurring as RNA polymerase II elongates along the template DNA. The C-terminal domain (CTD) of the largest subunit of RNA Pol II serves as a dynamic landing platform whose phosphorylation state recruits the appropriate processing factors at each stage of transcript maturation.

1

Co-transcriptional Processing

Capping, splicing, and polyadenylation occur while the transcript is still being synthesized. The CTD of RNA Pol II coordinates factor recruitment, ensuring orderly modification.
2

5ʹ Capping Protects & Signals

A 7-methylguanosine (m⁷G) cap is added via a 5ʹ–5ʹ triphosphate linkage, shielding mRNA from exonucleases and serving as a recognition element for ribosome binding and nuclear export.
3

Splicing Removes Introns

The spliceosome—a dynamic complex of five snRNPs and numerous proteins—excises introns and ligates exons through two sequential transesterification reactions, yielding a continuous coding sequence.
4

Polyadenylation Stabilizes the 3ʹ End

After endonucleolytic cleavage at a site downstream of the AAUAAA signal, poly(A) polymerase adds a tail of approximately 200 adenylate residues, promoting mRNA stability, export, and translation initiation.
5

Alternative Splicing Expands Diversity

By selectively including or excluding specific exons, a single gene can produce multiple mRNA isoforms—and thus multiple protein variants—providing an enormous layer of regulatory complexity.
KEY TAKEAWAY
Think of pre-mRNA processing like film editing. The raw footage (pre-mRNA) contains everything the camera recorded—useful scenes (exons) and unusable takes (introns). A film editor (the spliceosome) cuts out the bad takes and splices the good scenes together. Meanwhile, the opening title card (5ʹ cap) and the end credits (poly-A tail) are appended to create a polished, recognizable final product ready for the audience (the ribosome). In alternative splicing, the same raw footage yields multiple cuts—an action version, a director's cut, a romantic edit—each telling a slightly different story.

Visual Overview of RNA Processing

This diagram traces the four major steps of eukaryotic mRNA maturation. The raw pre-mRNA (step 1) contains alternating exons (colored blocks) and introns (translucent blocks). The m⁷G cap (green circle) is added at the 5ʹ end during step 2. Introns are excised via lariat formation during splicing (step 3), and the poly(A) tail is appended at the 3ʹ end (step 4), yielding a mature mRNA ready for nuclear export and translation.

As illustrated above, the three processing events occur in a defined temporal order, though they overlap extensively during transcription elongation. Capping occurs first, when the nascent transcript is only 20–30 nucleotides long. Splicing proceeds co-transcriptionally as the spliceosome assembles on intron sequences emerging from RNA Pol II. Polyadenylation is the final step, triggered when the polymerase transcribes through the polyadenylation signal. Importantly, all three events are coupled to the C-terminal domain (CTD) of RNA Pol II, a repetitive heptapeptide tail whose serine residues undergo differential phosphorylation to recruit the correct processing machinery at each stage. Phosphorylation of Ser5 of the CTD recruits capping enzymes, while Ser2 phosphorylation promotes splicing and polyadenylation factor binding.

Molecular Mechanisms of Each Modification

5ʹ Capping: Chemistry and Function

The 5ʹ cap is added in three enzymatic steps that occur while the nascent transcript is approximately 20–30 nucleotides long. First, RNA triphosphatase removes the terminal γ-phosphate from the 5ʹ end of the pre-mRNA, converting the 5ʹ triphosphate to a diphosphate. Second, guanylyltransferase catalyzes the addition of a GMP moiety in a unique 5ʹ–5ʹ triphosphate linkage—the only such bond in the cell. Third, methyltransferase adds a methyl group to the N-7 position of the guanine, yielding the m⁷GpppN structure. This unusual linkage is resistant to conventional 5ʹ exonucleases, conferring stability. The cap also recruits the cap-binding complex (CBC) in the nucleus for splicing and export, and eIF4E in the cytoplasm for translation initiation.

CAPPING REACTION
5ʹ-pppN-RNA → 5ʹ-ppN-RNA → m⁷GpppN-RNA
The γ-phosphate is removed first (RNA triphosphatase), then GMP is added via 5ʹ–5ʹ linkage (guanylyltransferase), and the guanine is methylated at N-7 (methyltransferase). p = phosphate; N = first transcribed nucleotide.

Splicing: The Spliceosome Mechanism

Intron removal is catalyzed by the spliceosome, a dynamic macromolecular complex composed of five small nuclear ribonucleoproteins (U1, U2, U4, U5, and U6 snRNPs) and over 100 associated proteins. The spliceosome recognizes three conserved sequence elements within each intron: the 5ʹ splice site (GU dinucleotide), the branch point (a conserved adenosine residue typically 18–40 nucleotides upstream of the 3ʹ splice site), and the 3ʹ splice site (AG dinucleotide). Splicing proceeds through two sequential transesterification reactions. In step one, the 2ʹ-hydroxyl of the branch-point adenosine attacks the phosphodiester bond at the 5ʹ splice site, forming a lariat intermediate with a 2ʹ–5ʹ phosphodiester bond. In step two, the free 3ʹ-OH of the upstream exon attacks the phosphodiester bond at the 3ʹ splice site, ligating the two exons and releasing the intron lariat for degradation.

TRANSESTERIFICATION STEP 1
Exon1–p–|GU...A...AG|–Exon2 → Exon1–OH + lariat(A-2ʹ,5ʹ-GU...AG)–Exon2
The 2ʹ-OH of the branch-point adenosine (A) performs nucleophilic attack on the 5ʹ splice site phosphodiester, generating a free 3ʹ-OH on Exon 1 and a lariat-shaped intron still attached to Exon 2.
TRANSESTERIFICATION STEP 2
Exon1–OH + lariat–Exon2 → Exon1–p–Exon2 + lariat (released)
The free 3ʹ-OH of Exon 1 attacks the 3ʹ splice site, joining the exons with a standard 3ʹ–5ʹ phosphodiester bond and releasing the lariat intron for debranching and degradation.

3ʹ Polyadenylation: Cleavage and Tail Addition

The 3ʹ end of eukaryotic mRNA is generated not by transcription termination per se, but by an endonucleolytic cleavage event followed by template-independent polymerization. The pre-mRNA contains a highly conserved AAUAAA hexamer (the polyadenylation signal) located 10–30 nucleotides upstream of the cleavage site, as well as a downstream GU-rich or U-rich element. These signals are recognized by cleavage and polyadenylation specificity factor (CPSF) and cleavage stimulation factor (CstF), respectively. Together with additional cleavage factors, they direct endonucleolytic scission of the transcript. Poly(A) polymerase (PAP) then adds approximately 200 adenylate residues without a template. The growing tail is bound by poly(A)-binding protein (PABP), which stabilizes the transcript, promotes nuclear export, and facilitates translation by interacting with initiation factors bound to the 5ʹ cap, effectively circularizing the mRNA.

Alternative Splicing and Proteomic Diversity

One of the most remarkable consequences of eukaryotic RNA processing is alternative splicing—the regulated inclusion or exclusion of specific exons (and occasionally intron retention) to generate multiple mRNA isoforms from a single gene. Current estimates suggest that over 95% of human multi-exon genes undergo some form of alternative splicing, making it a principal mechanism for expanding proteomic complexity. The selection of splice sites is governed by a combinatorial code of cis-regulatory elements (exonic/intronic splicing enhancers and silencers) and trans-acting factors (SR proteins and hnRNPs) that either promote or inhibit spliceosome assembly at particular splice sites.

Five major patterns of alternative splicing are depicted: (A) exon skipping (cassette exon), (B) alternative 5ʹ splice site selection, (C) intron retention, (D) alternative 3ʹ splice site selection, and (E) mutually exclusive exons. In each case, the same pre-mRNA yields distinct mature transcripts encoding potentially different protein products.

The most common pattern in vertebrate genomes is exon skipping (also called cassette exon usage), in which an internal exon is either included or excluded from the final mRNA. Alternative 5ʹ and 3ʹ splice site selection alters exon boundaries, changing the length of the included exon sequence and potentially shifting the reading frame. Intron retention, more prevalent in plants and lower eukaryotes, results in an intronic sequence remaining in the mature mRNA—often introducing a premature stop codon that targets the transcript for nonsense-mediated decay (NMD). Mutually exclusive exons represent a special case in which only one of two or more adjacent exons is ever incorporated, as seen in the Drosophila Dscam gene, which can theoretically produce over 38,000 isoforms through combinatorial exon selection.

⚕️ Clinical Relevance
Aberrant alternative splicing is a hallmark of many diseases. In spinal muscular atrophy (SMA), the SMN2 gene predominantly skips exon 7, producing a truncated, unstable protein. The FDA-approved antisense oligonucleotide drug nusinersen (Spinraza) works by modifying splicing of SMN2 to include exon 7, restoring functional SMN protein production—a direct therapeutic application of alternative splicing biology.

Worked Example: Tracing a Pre-mRNA Through Processing

Consider a hypothetical eukaryotic gene that contains four exons and three introns. The gene encodes a 1,200-nucleotide coding sequence distributed across its exons, and the pre-mRNA (including introns and UTRs) spans 8,500 nucleotides. We will trace this transcript through each processing step and determine the final size and composition of the mature mRNA.

Processing of a Hypothetical Pre-mRNA
1
Step 1 — Identify Pre-mRNA ComponentsThe pre-mRNA consists of: 5ʹ UTR (200 nt) + Exon 1 (300 nt) + Intron 1 (2,000 nt) + Exon 2 (250 nt) + Intron 2 (3,000 nt) + Exon 3 (350 nt) + Intron 3 (1,500 nt) + Exon 4 (300 nt) + 3ʹ UTR (400 nt) + downstream sequence (200 nt). Total pre-mRNA = 8,500 nt. The coding sequence is distributed across Exons 1–4 (300 + 250 + 350 + 300 = 1,200 nt), with the 5ʹ UTR in the beginning of Exon 1 region and the 3ʹ UTR following the stop codon in Exon 4.
Pre-mRNA total = 8,500 nt; total intron sequence = 6,500 nt
2
Step 2 — 5ʹ CappingWhen the nascent transcript reaches ~25 nt, the capping enzymes (recruited by Ser5-phosphorylated CTD) add the m⁷G cap via a 5ʹ–5ʹ triphosphate linkage. The cap is added to the very first nucleotide of the transcript. This step does not change the nucleotide length of the RNA but adds one m⁷G residue and the unusual linkage.
Product: m⁷Gppp–[pre-mRNA, 8,500 nt] (capped but unspliced)
3
Step 3 — Splicing (Intron Removal)The spliceosome assembles on each intron co-transcriptionally. For each of the three introns, U1 snRNP recognizes the 5ʹ splice site (GU), U2 snRNP binds the branch-point A, and the catalytic spliceosome (with U5 and U6) performs the two transesterification reactions. After removal of Intron 1 (2,000 nt), Intron 2 (3,000 nt), and Intron 3 (1,500 nt), a total of 6,500 nt of intronic sequence is excised as lariats. The remaining exonic sequence = 8,500 − 6,500 = 2,000 nt (this includes 5ʹ UTR, coding exons, and 3ʹ UTR up to the polyadenylation cleavage site).
Product: m⁷Gppp–[Exon 1–Exon 2–Exon 3–Exon 4 + UTRs] ≈ 2,000 nt (spliced, uncleaved)
4
Step 4 — 3ʹ Cleavage and PolyadenylationCPSF recognizes the AAUAAA signal in the 3ʹ UTR, and CstF binds the downstream GU-rich element. Endonucleolytic cleavage occurs 10–30 nt downstream of AAUAAA, removing the downstream 200 nt. Poly(A) polymerase then adds ~200 A residues. The final mature mRNA length = (2,000 − 200) nt of transcript + 200 nt of poly(A) tail = 2,000 nt total.
Mature mRNA: m⁷Gppp–[5ʹ UTR + Exon 1-2-3-4 + 3ʹ UTR]–AAAA(200) ≈ 2,000 nt
5
Step 5 — Calculate Processing EfficiencyThe fraction of the original transcript retained in the mature mRNA (excluding the poly(A) tail): (1,800 nt retained transcript) / 8,500 nt = 21.2%. This means roughly 78.8% of the transcribed sequence—nearly all of it intronic—was removed during processing. This is typical for mammalian genes, where introns often constitute >90% of the primary transcript in extreme cases.
Only ~21% of the original pre-mRNA is retained in the mature message; 79% is removed as introns and downstream cleavage product.

Functions and Regulation of Processing Modifications

Each processing modification serves multiple overlapping functions: protection from degradation, facilitation of nuclear export, and promotion of translation. Understanding how these functions interrelate—and how regulatory mechanisms control the fidelity and alternative outcomes of processing—is central to appreciating the logic of eukaryotic gene expression.

Comparison of eukaryotic mRNA processing modifications
ModificationKey FunctionsRegulatory FactorsConsequences of Defects
5ʹ Cap (m⁷G)Protection from 5ʹ exonucleases; recruitment of CBC for splicing and export; eIF4E binding for translation initiationRNA triphosphatase, guanylyltransferase, methyltransferase (recruited by Ser5-P CTD)Rapid transcript degradation; failure of nuclear export and translation
SplicingRemoval of non-coding introns; exon junction complex (EJC) deposition for NMD; mRNA compaction for exportU1, U2, U4, U5, U6 snRNPs; SR proteins (enhance); hnRNPs (repress); branch-point binding proteinRetained introns → premature stop codons → NMD; exon skipping → truncated or non-functional proteins; disease (e.g., β-thalassemia)
PolyadenylationmRNA stability via PABP binding; nuclear export; translational enhancement through mRNA circularization with eIF4GCPSF (binds AAUAAA), CstF (binds GU-rich element), PAP, PABP (recruited by Ser2-P CTD)Rapid 3ʹ→5ʹ degradation; impaired translation; aberrant 3ʹ end formation linked to cancer (e.g., shortened 3ʹ UTR in proliferating cells)
Alternative SplicingProteomic diversity; tissue-specific protein isoforms; developmental regulation; post-transcriptional gene regulation via NMDCombinatorial code of SR proteins and hnRNPs; ESE/ESS/ISE/ISS elements; chromatin state and Pol II elongation rateSpinal muscular atrophy (SMN2 exon 7 skipping); frontotemporal dementia (tau exon 10 missplicing); ~15% of all disease-causing point mutations disrupt splicing
KEY TAKEAWAY
The 5ʹ cap and poly(A) tail function as molecular bookends—they are recognized by the same translational machinery (eIF4E at the 5ʹ end and PABP at the 3ʹ end bridged by eIF4G), effectively circularizing the mRNA and ensuring that only fully processed, intact messages are efficiently translated. This circularization acts as a quality-control checkpoint: if either end is defective, the transcript is rapidly degraded rather than producing aberrant protein. Think of it as a molecular handshake—both ends of the mRNA must 'agree' that the message is complete before the ribosome is allowed to begin work.

Connections to Advanced Topics in Gene Regulation

RNA processing does not occur in isolation—it is deeply interconnected with chromatin biology, transcription dynamics, and post-transcriptional surveillance. Emerging research reveals that the rate of RNA polymerase II elongation directly influences splice-site selection: a slowly elongating polymerase allows weak upstream splice sites more time for spliceosome assembly, thereby promoting inclusion of alternative exons. This kinetic coupling model links epigenetic marks (like histone modifications that affect Pol II speed) to alternative splicing outcomes, bridging chromatin regulation and proteomic diversity.

Connecting RNA processing to advanced regulatory mechanisms
Concept in This LessonAdvanced Extension
Co-transcriptional processing via CTDCTD modifications form a 'CTD code' analogous to the histone code, recruiting not only processing factors but also chromatin remodelers, creating a bidirectional coupling between transcription and chromatin
Spliceosome-mediated intron removalSelf-splicing Group I and Group II introns (ribozymes) are evolutionary precursors of the spliceosome; Group II introns share the same two-step transesterification mechanism, supporting the RNA world hypothesis
Alternative splicing regulationSingle-cell RNA-seq and long-read sequencing (PacBio, Oxford Nanopore) now reveal cell-type-specific isoform landscapes, enabling splicing-aware transcriptomics and identification of cancer-specific splice variants as therapeutic targets
Poly(A) tail and mRNA stabilityCytoplasmic deadenylation by the CCR4–NOT complex is a major route of mRNA turnover; microRNAs accelerate deadenylation of target mRNAs, linking RNA processing to post-transcriptional silencing (RNAi pathway)
Exon junction complex (EJC) depositionThe EJC marks sites of splicing on the mRNA and triggers nonsense-mediated decay (NMD) if a premature stop codon lies >50 nt upstream of an EJC, providing a quality-control checkpoint for gene expression

As you advance in molecular biology, you will encounter RNA editing (A-to-I and C-to-U conversions), circular RNA biogenesis through back-splicing, and the growing appreciation that many 'non-coding' RNAs (lncRNAs, snoRNAs) themselves undergo complex processing pathways. The principles introduced here—enzymatic modification, sequence-specific recognition, dynamic ribonucleoprotein assembly, and regulatory combinatorics—form the conceptual foundation for understanding all of these advanced phenomena.

Practice Problems

PROBLEM 1CONCEPTUAL
Explain why the 5ʹ cap uses a 5ʹ–5ʹ triphosphate linkage rather than the standard 3ʹ–5ʹ phosphodiester bond. What advantage does this unusual chemistry confer on the mRNA?
PROBLEM 2BASIC CALCULATION
A eukaryotic pre-mRNA is 15,000 nucleotides long and contains 5 exons (sizes: 150, 300, 450, 200, and 400 nt) and 4 introns. After processing, the mature mRNA also includes a 5ʹ UTR of 100 nt, a 3ʹ UTR of 250 nt, and a poly(A) tail of 200 residues. Calculate (a) the total length of intron sequences removed, and (b) the total length of the mature mRNA.
PROBLEM 3INTERMEDIATE
A researcher mutates the branch-point adenosine of Intron 2 in a three-intron gene to a cytosine. Predict the effect on splicing of this intron and explain the molecular basis for your prediction. Would the other introns be affected?
PROBLEM 4APPLIED
The Drosophila Dscam gene has 95 alternative exons organized in four clusters of mutually exclusive exons (12, 48, 33, and 2 choices in each cluster). Calculate the theoretical number of distinct mRNA isoforms. Why is this diversity important for Dscam's biological function in axon guidance and immune self-recognition?
PROBLEM 5CRITICAL THINKING
Antisense oligonucleotide (ASO) therapies like nusinersen target specific pre-mRNA sequences to modulate splicing. Propose a general strategy by which an ASO could promote inclusion of a normally skipped exon. Your answer should address: (a) what type of cis-regulatory element the ASO might target, (b) the molecular mechanism of action, and (c) potential off-target risks.

Lesson Summary

Eukaryotic RNA processing transforms the nascent pre-mRNA into a mature, export-ready messenger through three co-transcriptional modifications coordinated by the C-terminal domain (CTD) of RNA Pol II. First, 5ʹ capping appends a 7-methylguanosine (m⁷G) via a unique 5ʹ–5ʹ triphosphate linkage, protecting the transcript and promoting ribosome recruitment. Second, the spliceosome (a complex of U1, U2, U4, U5, and U6 snRNPs) recognizes conserved splice sites and the branch-point adenosine, executing two transesterification reactions to excise introns as lariat intermediates and ligate exons. Third, 3ʹ polyadenylation—directed by the AAUAAA signal and carried out by CPSF, CstF, and poly(A) polymerase—adds a ~200-residue poly(A) tail that promotes stability, export, and translation.

Beyond constitutive processing, alternative splicing massively expands proteomic diversity by selectively including or excluding exons through a combinatorial code of cis-regulatory elements (ESEs, ESSs, ISEs, ISSs) and trans-acting factors (SR proteins and hnRNPs). The five major patterns—exon skipping, alternative 5ʹ/3ʹ splice sites, intron retention, and mutually exclusive exons—allow >95% of human multi-exon genes to produce multiple isoforms. Defects in RNA processing are linked to diseases including spinal muscular atrophy, β-thalassemia, and cancer, making this pathway both a fundamental aspect of gene expression and a critical frontier for therapeutic intervention.

Varsity Tutors • Cell Biology • RNA Processing — Explain RNA processing (capping, splicing, polyadenylation) and alternative splicing (conceptual)